<DOC>
	<DOCNO>NCT02009332</DOCNO>
	<brief_summary>Purpose study determine appropriate dose ABI-009 evaluate safety anti-tumor activity ABI-009 treatment non-muscle invasive bladder cancer</brief_summary>
	<brief_title>Phase 1/2 Study ABI-009 Nonmuscle Invasive Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Patients must diagnosis transitional cell carcinoma ( TCC ) urinary bladder confirm study institution . The patient must demonstrate nonmuscleinvasive recurrent bladder cancer refractory recurrent standard intravesical therapy . Patients must exhibit disease recurrence receive adequate intravesical BCG ( least 6 week induction plus 3 additional dos either induction maintenance ) . Patients history intravesical agent addition standard BCG also allow enroll . All grossly visible disease must fully resect pathologic stage confirm institution patient enrol . This include stage Ta , T1 , Tis exclude patient muscle invasion ( T2 ) . 1 . For phase 1 , patient multifocal lowgrade Ta histology eligible participation 2 . For phase 2 , individual Ta disease must documentation highgrade histology 2 . Age &gt; 18 must able read , understand , sign inform consent 3 . Performance Status : ECOG 0 , 1 , 2 ( See Appendix III ) 4 . Hematologic inclusion within 2 week start treatment 1 . Absolute neutrophil count &gt; 1,500/mm3 2 . Hemoglobin &gt; 9.0 g/dl 3 . Platelet count &gt; 100,000/mm3 5 . Hepatic inclusion within 2 week entry 1 . Total bilirubin must within normal limit . 2 . Adequate renal function serum creatinine ≤2.5 mg/dL 3 . Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤2.5 x ULN institution , alkaline phosphatase ≤ 2.5 x ULN institution , unless bone metastasis present absence liver metastasis 6 . Women childbearing potential must negative pregnancy test . 7 . All patient childbearing potential must willing consent use effective contraception , ie , intrauterine device , birth control pill , depoprovera , condom treatment 3 month participation study end . 1 . Any malignancy diagnose within 1 year study entry ( except basal squamous cell skin cancer noninvasive cancer cervix ) exclude 2 . Concurrent treatment chemotherapeutic agent 3 . Women pregnant lactate 4 . History vesicoureteral reflux indwell urinary stent 5 . Participation research protocol involve administration investigational agent within 1 month prior study entry 6 . History radiation pelvis 7 . History interstitial lung disease and/or pneumonitis 8 . Evidence metastatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>